Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery
Year: 2014
Type: letter
Abstract: We read with interest the Review by Forner and colleagues (Treatment of intermediate-stage hepatocellular carcinoma Nat. Rev. Clin. Oncol. 11 , 525–535; 2014), 1 which focused on recent advances in the stratification of and treatment allocation for patients with intermediate-stage hepatocellular carcinoma (HCC), that is, Barcelona Clinic Liver Cancer (BCLC) stage B disease. We agree with the authors that the patient population with intermediate-stage HCC is highly heterogeneous with regard to tumour burden, liver function, and clinical characteristics. However, according to Forner et al ., 1 transarterial chemoembolization (TACE) and sorafenib should be the only standard treatments for intermediate-stage HCC. We disagree with this stance, as studies in both Eastern and Western countries have indicated that hepatic resection is safe and results in longer survival in selected patients with intermediate-stage HCC as compared with TACE and/or sorafenib therapy. 2 , 3
Source: Nature Reviews Clinical Oncology
Authors: Qiang Gao, Xiao-Ying Wang, Jian Zhou, Jia Fan
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2009584962